Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1, and cT2N0 esophageal adenocarcinoma with indication for radical surgery: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group (IKF-t057/PRESTO trial).

Authors

null

Thorsten Goetze

Krankenhaus Nordwest, University Cancer Center Frankfurt, Frankfurt Am Main, Germany

Thorsten Goetze , Stefan Angermeier , Juergen Debus , Vera Heuer , Nils Homann , Stephan Kanzler , Stefan Kubicka , Ruediger Liersch , Sylvie Lorenzen , Rolf Mahlberg , Christian Mueller , Lothar Mueller , Daniel Pink , Mark Reinwald , Ulrich Ronellenfitsch , Ludwig Fischer von Weikersthal , Ulas Tenekeci , Claudia Pauligk , Salah-Eddin Al-Batran

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers

Track

Esophageal and Gastric Cancer,Small Bowel Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05713838

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr TPS431)

DOI

10.1200/JCO.2024.42.3_suppl.TPS431

Abstract #

TPS431

Poster Bd #

N16

Abstract Disclosures